Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
03/06	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
20/05	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/24/11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/24/29	CoTec Holdings Outlines Key Targets For 2024	MT
03/24/03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/23/10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/23/10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/23/02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/23/14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/23/14	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/23/30	Kings Chapel Increases Stake In CoTec Holdings	MT

06/05	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
01/16/01	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/16/29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/16/15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/16/12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	7.04TCr
ARGENX SE	+1.09%	+3.40%	+51.59%	+93.39%	6.54TCr
BIONTECH SE	-1.03%	-1.52%	+6.31%	-5.28%	2.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.49%	+5.43%	+54.81%	+13.87%	2.66TCr
INSMED INCORPORATED	-2.41%	-7.09%	-8.16%	+455.82%	2.72TCr
GENMAB A/S	+0.37%	+0.70%	+37.37%	-15.78%	2.01TCr
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	2.06TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	+0.19%	+8.01%	+520.34%	1.59TCr
EXELIXIS, INC.	-1.50%	+1.60%	+44.13%	+151.30%	1.39TCr
Average	+0.47%	+1.16%	+58.28%	+193.07%	3.2TCr
Weighted average by Cap.	+1.11%	+0.72%	+55.95%	+155.10%